| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,329,171 | -4,074,217 | -4,177,423 | -8,867,798 |
| Depreciation and amortization | 3,853 | 4,103 | 4,102 | 9,075 |
| Realized gain on redemptions of available for sale debt securities | NaN | 119 | -345 | 22,634 |
| Non-cash lease adjustments | 18,727 | 43,002 | 146,895 | NaN |
| Realized loss on equity securities | NaN | 49,988 | 72,677 | 142,248 |
| Issuance of restricted common stock for services | NaN | 232,800 | 134,100 | NaN |
| Vesting of restricted common stock issued for services | 38,800 | NaN | NaN | NaN |
| Stock-based compensation | 262,915 | 198,816 | 143,685 | 308,376 |
| Write-off of deferred offering costs | 33,604 | NaN | NaN | NaN |
| Accretion of discounts on available for sale debt securities, net | 20,172 | 25,487 | 38,015 | 132,925 |
| Foreign currency remeasurement gain | 77,286 | 19,488 | 8,912 | 129,565 |
| Unrealized loss (gain) on equity securities | -59,451 | 42,592 | 95,906 | 167,389 |
| Prepaid expenses and other current assets | 49,508 | -415,005 | -201,223 | 62,133 |
| Accounts payable and accrued expenses | -705,025 | 466,998 | -806,921 | 611,731 |
| Operating lease liabilities | -19,463 | -40,922 | -51,085 | -98,618 |
| Changes in operating right-of-use assets | NaN | NaN | NaN | 96,745 |
| Other assets | -10,648 | NaN | NaN | 0 |
| Net cash flows used in operating activities | -3,772,627 | -2,792,113 | -4,571,980 | -8,312,887 |
| Purchase of property and equipment | NaN | 1 | 555 | 1,159 |
| Purchase of marketable securities | NaN | 4,204,493 | 2,076,794 | 8,440,696 |
| Redemptions of marketable securities | 4,250,000 | 2,500,540 | 8,005,887 | 15,274,344 |
| Net cash flows provided by investing activities | 4,250,000 | -1,703,954 | 5,928,538 | 6,832,489 |
| Proceeds from option exercises | NaN | 0 | 13,442 | NaN |
| Proceeds from the issuance of common stock under the atm sales agreement | NaN | 666,208 | 958,339 | NaN |
| Proceeds from warrant exercises | NaN | NaN | NaN | 0 |
| Payments of offering cost related to the atm sales agreement | NaN | 139,749 | NaN | NaN |
| Net cash flows provided by financing activities | NaN | 526,459 | 971,781 | 0 |
| Effect of foreign exchange rates on cash | 17,585 | 2,960 | -261 | 30,727 |
| Change in cash and cash equivalents for the period | 494,958 | -3,966,648 | 2,328,078 | -1,449,671 |
| Cash and cash equivalents, beginning of period | 4,422,838 | 8,389,486 | 7,511,079 | NaN |
| Cash and cash equivalents, end of period | 4,917,796 | 4,422,838 | 8,389,486 | NaN |
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)